Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
基本信息
- 批准号:8502610
- 负责人:
- 金额:$ 32.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-05 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdoptive TransferApoptosisBiological AssayBone MarrowBone Marrow TransplantationBoxingCell LineCell LineageCell SurvivalCellsComplementComplicationCoupledCytomegalovirusCytomegalovirus InfectionsDNADataDefectDevelopmentDiseaseGTP-Binding ProteinsGoalsHerpesviridaeHomologous GeneHumanITGAM geneImmunocompromised HostIn VitroIndividualInfectionIntegration Host FactorsKnowledgeLabelLeadLettersLifeMaintenanceMediatingMethodsMicroarray AnalysisMorbidity - disease rateMusMyelogenousMyeloid CellsOutcomePathogenesisPatientsPopulationPreventionPublic HealthResearchResourcesRoleSignal PathwaySignal TransductionSpleenTestingTransgenic MiceTransplant RecipientsViralViral GenomeVirusWorkbasebeta-Chemokinescell typechemokine receptorin vitro Assayin vivoinnovationlatent infectionmonocytemortalitymutantneonatenovel therapeuticspathogenpreventprogenitorreactivation from latencytherapeutic developmentviral DNAvirology
项目摘要
DESCRIPTION (provided by applicant): Reactivation of Human Cytomegalovirus (HCMV) from latency is the most common infectious complication in bone marrow transplant patients, with significant morbidity and mortality. Very little is known about the viral/host interactions governing the establishment and maintenance of long term HCMV infection. The long-term goal is to identify the viral and host mechanisms that lead to the development of CMV latency. The objective of this proposal is to determine the role of the CMV-encoded chemokine receptors in the establishment of latency in progenitor myeloid lineage cells and to identify the host signaling pathways that promote CMV establishment of latency. The central hypothesis is that the CMV-encoded chemokine receptors activate host signaling pathways which aid in the establishment of latency during in vivo infection. Project Summary: Our hypothesis is based on strong preliminary data which demonstrates that murine CMV (MCMV) lacking M33 does not efficiently establish latent infection and that M33-deficient viruses which express the HCMV-encoded chemokine receptors, UL33 or US28, complements this latency defect in vivo. Three specific aims will be pursued: 1) Identify the myeloid lineage cell type which requires M33 for the establishment and/or maintenance of CMV latency in vivo, 2) Identify the mechanisms underlying the role of M33 during infection in monocytes, and 3) Identify the M33-mediated signaling pathway (s) required for establishment and/or maintenance of CMV latency. This aim will utilize specific M33 mutant viruses coupled with microarray analysis to identify signaling pathways which are modulated by M33 and US28. The approach is innovative, and uses a multifaceted approach to identify the host and viral factors involved in the establishment and/or maintenance of CMV latency in myeloid lineage cells. The proposed research is significant, because it is expected to lead to the development of therapeutic strategies aimed at preventing CMV latency and complications due to reactivation of latent CMV. Relevance to Public Health: The new knowledge obtained will lead to the prevention of CMV latency and reactivation in immunocompromised patients, such transplant patients, neonates, and AIDS patients, where CMV infection leads to significant morbidity and mortality.
描述(由申请人提供):人巨细胞病毒(HCMV)潜伏期重新激活是骨髓移植患者最常见的感染性并发症,具有显著的发病率和死亡率。关于病毒/宿主之间的相互作用控制着人类巨细胞病毒长期感染的建立和维持,人们知之甚少。长期目标是确定导致CMV潜伏期发展的病毒和宿主机制。本研究的目的是确定CMV编码的趋化因子受体在建立祖细胞系髓系细胞潜伏期中的作用,并确定促进CMV潜伏期建立的宿主信号通路。中心假设是CMV编码的趋化因子受体激活宿主信号通路,帮助建立体内感染期间的潜伏期。项目摘要:我们的假设建立在强大的初步数据基础上,这些数据表明,缺乏M33的小鼠CMV(MCMV)不能有效地建立潜伏感染,并且表达HCMV编码的趋化因子受体UL33或US28的M33缺陷病毒在体内补充了这一潜伏缺陷。我们将追求三个特定的目标:1)鉴定建立和/或维持体内巨细胞病毒潜伏期需要M33的髓系细胞类型;2)鉴定M33在单核细胞感染过程中所起作用的机制;3)鉴定建立和/或维持巨细胞病毒潜伏期所需的M33介导的信号通路(S)。这一目标将利用特定的M33突变病毒结合微阵列分析来识别由M33和US28调制的信号通路。该方法是创新的,使用多方面的方法来识别在髓系细胞中建立和/或维持CMV潜伏期所涉及的宿主和病毒因素。这项拟议的研究具有重要意义,因为它有望导致旨在预防CMV潜伏期和因潜伏性CMV重新激活而引起的并发症的治疗策略的发展。与公共卫生相关:获得的新知识将导致预防免疫低下患者的CMV潜伏期和重新激活,如移植患者、新生儿和艾滋病患者,在这些患者中,CMV感染会导致显著的发病率和死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rhonda D Cardin其他文献
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
用于治疗 COVID-19 的第二代口服 SARS-CoV-2 主要蛋白酶抑制剂临床候选药物。
- DOI:
10.1021/acs.jmedchem.3c02469 - 发表时间:
2024 - 期刊:
- 影响因子:7.3
- 作者:
C. Allerton;Joel T. Arcari;L. Aschenbrenner;Melissa Avery;B. Bechle;Mohammad Amin Behzadi;B. Boras;Leanne M. Buzon;Rhonda D Cardin;Natasha R Catlin;Anthony A Carlo;Karen J. Coffman;A. Dantonio;Li Di;Heather Eng;Kathleen A. Farley;Rose Ann Ferre;Steven S Gernhardt;Scott A Gibson;S. Greasley;Siennah R. Greenfield;B. Hurst;A. Kalgutkar;Emi Kimito;L. Lanyon;Gabrielle H Lovett;Yajing Lian;Wei Liu;Luis A Martínez Alsina;Stephen Noell;R. Obach;Dafydd R Owen;Nandini C Patel;Devendra K Rai;M. Reese;H. Rothan;Sylvie K. Sakata;M. Sammons;Jean G Sathish;Raman Sharma;C. Steppan;J. Tuttle;P. Verhoest;Liuqing Wei;Qingyi Yang;Irina Yurgelonis;Yuao Zhu - 通讯作者:
Yuao Zhu
Rhonda D Cardin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rhonda D Cardin', 18)}}的其他基金
Center for Experimental Infectious Disease Research
实验传染病研究中心
- 批准号:
9265314 - 财政年份:2014
- 资助金额:
$ 32.34万 - 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
- 批准号:
8680118 - 财政年份:2012
- 资助金额:
$ 32.34万 - 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
- 批准号:
8867123 - 财政年份:2012
- 资助金额:
$ 32.34万 - 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency
病毒趋化因子受体在巨细胞病毒潜伏期中的作用
- 批准号:
9284685 - 财政年份:2012
- 资助金额:
$ 32.34万 - 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
- 批准号:
8235473 - 财政年份:2012
- 资助金额:
$ 32.34万 - 项目类别:
ROLE OF ALPHA GENE PRODUCTS IN CMV LATENCY
ALPHA 基因产物在 CMV 潜伏期中的作用
- 批准号:
2058561 - 财政年份:1993
- 资助金额:
$ 32.34万 - 项目类别:
ROLE OF ALPHA GENE PRODUCTS IN CMV LATENCY
ALPHA 基因产物在 CMV 潜伏期中的作用
- 批准号:
3030576 - 财政年份:1992
- 资助金额:
$ 32.34万 - 项目类别:
ROLE OF ALPHA GENE PRODUCTS IN CMV LATENCY
ALPHA 基因产物在 CMV 潜伏期中的作用
- 批准号:
3030575 - 财政年份:1992
- 资助金额:
$ 32.34万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 32.34万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 32.34万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 32.34万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 32.34万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 32.34万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 32.34万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 32.34万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 32.34万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 32.34万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 32.34万 - 项目类别:














{{item.name}}会员




